|
Jul 30
|
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
|
|
Jul 29
|
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 29
|
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
|
|
Jul 29
|
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
|
|
Jul 29
|
Roche acquires Point of Care technology from LumiraDx
|
|
Jul 29
|
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
|
|
Jul 26
|
Roche records 4% decline in H1 2024 net income
|
|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
|
|
Jul 25
|
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
|
|
Jul 25
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
|
|
Jun 27
|
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
|
|
Jun 26
|
Pharma M&A: The top high value deals in 2023
|
|
Jun 25
|
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
|
|
Jun 25
|
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
|
|
Jun 24
|
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
|
|
Jun 10
|
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
|
|
Jun 10
|
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
|
|
Jun 10
|
European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
|